XAGE-3 siRNA (h): sc-90960



The Power to Question

BACKGROUND

XAGE-3 (X antigen family, member 3), also known as PLAC6 (placenta-specific gene 6 protein), GAGED4 (G antigen family D member 4), CT12.3a (cancer/testis antigen 12.3), CT12.3b or pp9012, is a 111 amino acid protein that belongs to the GAGE family and XAGE subfamily. XAGE-3 is thought to play a role in inhibition of cancer cell growth and is expressed primarily in placenta and fetal liver and spleen. The gene encoding XAGE-3 maps to human chromosome X, which consists of about 153 million base pairs and nearly 1,000 genes. The combination of a X and Y chromosome lead to normal male development while two copies of X lead to normal female development. There are a number of conditions related to an unusual number and combination of sex chromosomes being inherited, including Turner's syndrome, Klinefelter's syndrome and triple X syndrome. Color blindness, hemophilia, and Duchenne muscular dystrophy are well known X chromosome-linked conditions which affect males more frequently as males carry a single X chromosome.

REFERENCES

- Risco, J., Pardo, C., Figuera, E., Pellicer, F. and Año, T. 1992. Jugular phlebectasia. Apropos a case. Acta Otorrinolaringol. Esp. 43: 67-69.
- Brinkmann, U., Vasmatzis, G., Lee, B. and Pastan, I. 1999. Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res. 59: 1445-1448.
- Gianfrancesco, F., Sanges, R., Esposito, T., Tempesta, S., Rao, E., Rappold, G., Archidiacono, N., Graves, J.A., Forabosco, A. and D'Urso, M. 2001. Differential divergence of three human pseudoautosomal genes and their mouse homologs: implications for sex chromosome evolution. Genome Res. 11: 2095-2100.
- Bernardino-Sgherri, J., Flagiello, D. and Dutrillaux, B. 2002. Overall DNA methylation and chromatin structure of normal and abnormal X chromosomes. Cytogenet. Genome Res. 99: 85-91.
- Zendman, A.J., Van Kraats, A.A., Weidle, U.H., Ruiter, D.J. and Van Muijen, G.N. 2002. The XAGE family of cancer/testis-associated genes: alignment and expression profile in normal tissues, melanoma lesions and Ewing's sarcoma. Int. J. Cancer 99: 361-369.
- Bojesen, A., Kristensen, K., Birkebaek, N.H., Fedder, J., Mosekilde, L., Bennett, P., Laurberg, P., Frystyk, J., Flyvbjerg, A., Christiansen, J.S. and Gravholt, C.H. 2006. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care 29: 1591-1598.
- Maggio, M.C., Liotta, A., De Grazia, E., Cimador, M., Di Pace, R. and Corsello, G. 2007. Polycystic ovary and gonadoblastoma in Turner's syndrome. Minerva Pediatr. 59: 397-401.

CHROMOSOMAL LOCATION

Genetic locus: XAGE3 (human) mapping to Xp11.22.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

PRODUCT

XAGE-3 siRNA (h) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μM solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see XAGE-3 shRNA Plasmid (h): sc-90960-SH and XAGE-3 shRNA (h) Lentiviral Particles: sc-90960-V as alternate gene silencing products.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNAse-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

XAGE-3 siRNA (h) is recommended for the inhibition of XAGE-3 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com